PATH vs VTGN
Uipath Inc (PATH) versus VistaGen Therapeutics Inc (VTGN) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
VistaGen Therapeutics Inc (VTGN) is a biotechnology company listed on NASDAQ.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported VTGN revenue for 2023-03-31 was $176.0K. Net income was -$12.2M. VTGN currently screens at market cap $28.1M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. VTGN currently screens at market cap $28.1M.
Not investment advice. Open the PATH and VTGN stock pages for the full models.
Not investment advice.